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Abstract: As the population ages, the burden of osteoporosis in men is expected to rise. 
Implementation of preventive measures such as falls prevention strategies, exercise and 
adequate calcium and vitamin D intake is recommended. However, when the diagnosis of 
osteoporosis is made, effective treatments need to be initiated to prevent fractures. As opposed 
to postmenopausal women, reduced bone formation is the predominant mechanism of age-related 
bone loss in men, making anabolic agents a logical treatment option for men with osteoporosis. 
Teriparatide is the only anabolic agent currently approved for treatment of osteoporosis in 
men. This paper summarizes the mechanism of action of teriparatide, as well as its tolerability 
and safety. Furthermore, the evidence supporting the efﬁ  cacy of teriparatide treatment in men 
with osteoporosis is reviewed and its current role in the management of osteoporosis in men 
is discussed.
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Osteoporosis in men
Scope of the problem
Although the majority of research on osteoporosis in the past has focused on women, 
osteoporosis is also becoming an increasingly important problem in men. One in 8 men 
aged over 50 will have an osteoporosis-related fracture (Cooper and Melton 1992) 
and this ﬁ  gure is predicted to rise with an aging male population (Burge et al 2007). 
Although fragility fractures in men occur an average of 10 years later compared with 
those in women (Bilezikian 2000), most clinical fractures result in greater morbidity 
and mortality (Johnell et al 2001). Hip fractures are the most important for health 
outcomes, quality of life, and costs (Chang et al 2004) with mortality reaching 37.5% 
in the year after the fracture (Jiang et al 2005). Vertebral fractures also carry their share 
of morbidity and mortality in men. Even though most vertebral fractures are painless, 
they are associated with height loss, reduced quality of life, respiratory dysfunction, 
social withdrawal (Burger et al 1997; Scane et al 1999) and decreased survival (Lau 
et al 2008). Finally, a history of low-trauma fracture, including asymptomatic vertebral 
fracture, increases the risk for hip and other clinical fractures (Melton et al 1999; 
Klotzbuecher et al 2000). However, despite these alarming statistics and the availability 
of effective treatment options, osteoporosis continues to be under-recognized in men, 
with the majority of those with fractures going untreated (Meryn 2005).
Factors contributing to osteoporosis in men
Osteoporosis in men can be classified as primary or secondary, with primary 
osteoporosis often divided into idiopathic and age-related based on the age of 
diagnosis. Primary osteoporosis comprises approximately half the cases in men and is 
a heterogeneous multi-factorial condition referring to the development of osteoporosis 
when no secondary cause is identiﬁ  ed (Khosla et al 2008).Clinical Interventions in Aging 2008:3(4) 636
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Age-related bone loss usually occurs in men over the age of 
70 years due to a combination of nutritional and hormonal deﬁ  -
ciencies (Khosla et al 2008). The decrease in intestinal calcium 
absorption and high prevalence of vitamin D insufﬁ  ciency 
and deﬁ  ciency seen in elderly men both contribute to elevated 
serum parathyroid hormone (PTH) levels and bone loss (Lips 
2001). Other potential mechanisms by which sufﬁ  cient vita-
min D levels might preserve bone health are induction of osteo-
blastogenesis and osteoblastic activity, activation of osteogenic 
genes, prevention of osteoblast apoptosis and inhibition of 
bone marrow adipogenesis (Duque et al 2004a, b, 2005). Many 
other hormonal factors have also been incriminated in the 
pathophysiology of age-related bone loss in men. Both free or 
bioavailable testosterone and estradiol levels decline with age 
due to increased serum sex-hormone binding globulin (SHBG) 
levels and failure of the hypothalamic-pituitary-testicular axis 
to compensate (Khosla et al 1998; Orwoll et al 2006). Although 
cumulating evidence supports a dominant role of estrogen in 
maintaining bone mass in men, testosterone also contributes 
(Falahati-Nini et al 2000; Leder et al 2003; Amin et al 2006). 
Age-related decreases in insulin-like growth factor 1 (IGF-1) 
and increases in insulin-like growth factor binding protein 2 
(IGFBP-2) levels may also impair bone formation directly or 
via an increase in serum SHBG levels (Amin et al 2004, 2007). 
On the other hand, 85% of cases of secondary osteoporosis in 
men are explained by glucocorticoid use, hypogonadism, and 
excessive alcohol intake (Ebeling 1998, 2008). These factors 
are present in the majority of younger men with osteoporosis 
(Orwoll and Klein 2001) and may be superimposed on primary 
osteoporosis (Khosla et al 2008).
Pattern of bone loss in men – importance 
of reduced bone formation on trabecular 
and cortical bone loss
Both trabecular and cortical bone loss contribute to an 
age-related reduction in bone mass. Trabecular bone, 
predominantly found in the vertebrae, begins to decline before 
midlife in both sexes, but to a lesser extent in men, with 42% 
of trabecular bone being lost before age 50 (Riggs et al 2008). 
In contrast, cortical bone mass remains relatively stable until 
midlife, then decreases linearly in both men and women, 
with the decline being greater in females (Riggs et al 2008). 
Cortical bone loss occurs later in life from around the age of 
65 years in men, as the total surface available for trabecular 
remodeling decreases, causing bone remodeling to move from 
the trabecular to cortical compartment (Seeman 2002). The 
balance between endosteal bone resorption and simultaneous 
periosteal apposition determines the net decrease in cortical 
bone area. Although the amount of endosteal bone lost during 
aging is similar in men and women, periosteal bone gained is 
greater in men (Garn et al 1972; Seeman 2002; Ahlborg et al 
2003). Structural failure emerges during ageing because peri-
osteal bone formation incompletely offsets fragility produced 
by bone loss and architectural destruction inside bone.
The pattern of age-related changes in bone structure is 
an important factor in the pathophysiology of bone loss. 
In men, trabecular bone loss occurs by reduced bone 
formation, resulting in trabecular thinning, with mainte-
nance of trabecular number and connectivity. Conversely, 
bone resorption is the predominant mechanism of bone loss 
in postmenopausal women, resulting in a greater reduction 
in trabecular number and subsequent loss of connectivity and 
trabecular perforation (Aaron et al 1987) (Figure 1). Although 
both trabecular thinning and reduced trabecular number are 
associated with lower bone density, the latter has the greatest 
impact on bone strength (Silva and Gibson 1997), explaining 
in part the lower lifetime risk of fractures in men.
Current management 
of osteoporosis in men
Preventive measures
Exercise and falls prevention
In healthy older men, high-intensity progressive resistance 
training, weight-bearing impact exercise, or the combination 
of the two, increased bone mineral density (BMD) compared 
with controls (Kukuljan et al 2006). Although clinical trials 
have not yet shown that these BMD changes translate into 
reduced fracture risk, observational data suggests that older 
men who maintain an active lifestyle have a lower fracture 
risk (Michaelsson et al 2007). Meta-analyses of trials in older 
adults show that balance and strengthening exercises reduce 
the risk of falls (Carter et al 2001; Lord et al 2003), and 
given that a propensity to fall puts people with osteoporosis 
at greater risk for fracture, falls prevention strategies should 
be implemented (Tinetti 2003).
Calcium and vitamin D
Although data on the beneﬁ  t of calcium and vitamin D on 
fracture prevention are inconsistent, a recent systematic 
review of 17 randomized trials involving over 50,000 par-
ticipants showed that calcium alone or in combination with 
vitamin D reduces osteoporotic fractures by 12% among 
both men and women aged over 50 (Tang et al 2007). When 
analysis was performed on the 8 trials (n = 4,508) that 
reported a compliance rate of at least 80%, the risk reduction 
was doubled (24%). The treatment effect was also greater Clinical Interventions in Aging 2008:3(4) 637
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when at least 1,200 mg of calcium and 800 IU of vitamin 
D were taken. Vitamin D doses of at least 800 IU daily are 
therefore recommended, with the goal of maintaining a 
serum 25-hydroxyvitamin D level 30 ng/mL (75 nmol/L) 
(Vieth et al 2001).
Pharmacotherapy
Pharmacological agents have not been as well studied in men 
with osteoporosis as in women, and only a few treatments 
have been approved for use in men. These include bisphos-
phonates and teriparatide.
Bisphosphonates
Bisphosphonate therapy has been shown to be effective in 
increasing BMD in men with primary osteoporosis, as well 
as in men with secondary osteoporosis, including hypogo-
nadism and glucocorticoid-induced osteoporosis (Orwoll 
et al 2000; Ringe et al 2006). Although most trials of oral 
bisphosphonates in men have been either underpowered or 
not primarily designed to assess their effect on fracture inci-
dence, some trials showed a signiﬁ  cant 60%–88% reduction 
in the occurrence of new radiologic vertebral fractures 
(Orwoll et al 2000; Ringe et al 2006). Although the increase 
in BMD with bisphosphonate therapy is similar in men and 
women (Ho et al 2000) and could therefore theoretically 
translate into a reduction of fracture risk similar to the one 
observed in women, more data are required to ascertain the 
beneﬁ  ts of oral bisphosphonates on non-vertebral and hip 
fractures in men. Zoledronic acid is a potent intravenously 
administered bisphosphonate whose effects on fracture risk 
been assessed in a recent randomized placebo-controlled trial 
involving elderly men and women who had recently suffered 
a hip fracture (Lyles et al 2007). Yearly administration of 
5 mg of zoledronic acid for a median of 1.9 years within 
3 months of the fracture reduced the occurrence of overall 
new clinical fractures and mortality, but not hip fractures. 
Bisphosphonates are generally well tolerated. However, both 
intravenous and oral bisphosphonates have been linked in rare 
cases to osteonecrosis of the jaw, although current limited 
data suggest no clear increase in the risk of this complication 
in patients with osteoporosis (Bilezikian 2006). Rare case 
reports of atypical femoral diaphyseal fractures in patients 
on bisphosphonate therapy have also recently emerged in the 
literature and raise concerns about the long-term safety of 
this treatment in some individuals (Goh et al 2007; Lenart 
et al 2008; Visekruna et al 2008). However, more data are 
required on these atypical fractures.
Teriparatide as a new 
option for the treatment 
of osteoporosis in men
Teriparatide: why is it different?
Anticatabolic therapies such as bisphosphonates act by 
inhibiting osteoclast activity causing a decrease in bone 
resorption and depth of resorption cavities. Because bone 
remodeling is a coupled process, this decrease in osteoclast 
activity is accompanied by a decrease in osteoblast activity 
(Balena et al 1993; Draper et al 1996). This low turnover 
state leads to an improvement in BMD by increasing the 
time for matrix mineralization (Meunier and Boivin 1997). 
Anticatabolic therapies halt bone loss but do not add new 
(a) (b)
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Figure 1 Gender differences in pattern of cortical (a) and trabecular (b) bone loss resulting in trabecular and cortical thinning in men and increased cortical porosity and 
trabecular perforation in women. Reproduced with permission from Seeman E. 2002. Pathogenesis of bone fragility in women and men. Lancet, 359:1841–50. Copyright © 2002 
Elsevier.Clinical Interventions in Aging 2008:3(4) 638
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bone, nor do they restore disrupted microarchitecture. In 
severe cases of osteoporosis, putting a stop to further bone 
loss may not be enough to prevent further fractures. In these 
cases, treatments that stimulate bone formation and reverse 
skeletal deterioration may provide a valuable treatment 
option (National Cancer Institute 2001). In men, where 
decreased bone formation is an important etiological factor, 
an anabolic treatment seems a logical approach. Teriparatide 
is the only anabolic agent currently approved for treatment 
of osteoporosis in men.
Molecular structure of parathormone 
and teriparatide
The native hormone secreted by the parathyroid gland chief 
cell is human parathyroid hormone [hPTH (1–84)], a single-
chain polypeptide with 84 amino acids (Quattrocchi and 
Kourlas 2004). The knowledge of the molecular structure of 
PTH allowed the production of hPTH (1–84) for treatment 
in humans. Moreover, the discovery that the N-terminal 
34 amino acid portion of the native PTH molecule could fully 
activate the PTH/PTHrP receptor (Reeve et al 1980) led to 
the generation of pharmacological products comprising only 
this portion, such as hPTH (1–34) and recombinant human 
PTH [rhPTH (1–34)]. Teriparatide is the generic name for 
all PTH (1–34) molecules.
Anabolic effects of teriparatide on bone
Continuous high circulating PTH levels versus intermittent 
peaks of PTH have opposite effects on bone metabolism. 
The former has catabolic effects on bone as shown in people 
with primary hyperparathyroidism whereas administration 
of low-dose (20 μg/d), intermittent PTH, has an anabolic 
effect (Tam et al 1982). Although there have been advances 
in understanding the molecular and cellular events associated 
with activation of the PTH receptor in bone, the mechanism 
of action of teriparatide remains incompletely elucidated. 
Based on bone marker studies, teriparatide increases both 
bone formation and resorption. However, in the ﬁ  rst 3 months 
of treatment, there is a period known as “the anabolic 
window” where PTH stimulates bone formation to a greater 
extent than bone resorption, suggesting that teriparatide 
could initially induce bone apposition without prior bone 
resorption through modeling-based formation (Dempster 
2001; Bilezikian 2008). After 3–6 months of teriparatide 
treatment, the bone remodeling rate is globally increased, 
with bone formation favored over bone resorption resulting 
in a net gain of bone deposited in each basic multicellular unit 
(BMU). Teriparatide’s effect on bone formation is mediated 
by an increase in the number of osteoblasts via activation of 
osteoprogenitor differentiation and prevention of osteoblast 
apoptosis (Nishida et al 1994; Jilka et al 1999). Its anabolic 
effect on bone could also be indirect, through induction of 
IGF-1 synthesis in osteoblasts and downregulation of growth 
factor antagonists, such as sclerostin (Canalis et al 1989; 
Miyakoshi et al 2001; Bellido 2006).
Safety and tolerability
Frequent adverse effects
Adverse events reported during large phase III trials with 
teriparatide have generally been mild (Orwoll et al 2003). 
Most frequent adverse events associated with teriparatide 
20 μg sc daily were dizziness and leg cramps, and these 
occurred in fewer than 10% of treated patients. Injection 
site hypersensitivity occurred in a small number of patients. 
Allergic reactions, including dyspnea, urticaria, and chest 
pain, occurred in fewer than 1 in 1000 teriparatide recipients 
(Gold et al 2006).
Hypercalcemia and hypercalciuria
Six percent of men experienced mild transient hypercalce-
mia in phase III trials. It appeared generally 4–6 hours after 
teriparatide administration and resolved within 24 hours 
(Orwoll et al 2003). If hypercalcemia occurs, it is generally 
recommended to reduce calcium intake to 1,000 mg daily 
or less or to decrease the dose or frequency of teriparatide. 
Monitoring of serum calcium is not considered to be a routine 
requirement during treatment with teriparatide. However, 
measuring serum calcium at baseline and after a month of 
therapy could be a good practice (Stroup et al 2003; Hodsman 
et al 2006). Likewise, a recent study evaluating the effect of 
teriparatide on urinary calcium at 1, 6, and 12 months in two 
large placebo-controlled trials (Neer et al 2001; Orwoll et al 
2003) showed that increases in urinary calcium excretion 
were small and that less than 1% of the participants required 
a change in calcium or teriparatide dose due to hypercalci-
uria (Miller et al 2007). Since subjects with impaired renal 
function or with a history of kidney stones were excluded 
in these trials, it might be considered to monitor urinary 
calcium in patients with hypercalciuria at baseline or with 
a history of urolithiasis; however, no ﬁ  rm guidelines have 
been established on the follow-up of this rare adverse effect 
(Hodsman et al 2006; Miller et al 2007).
Osteosarcoma
So far, only one case of osteosarcoma associated with 
teriparatide has been reported in humans (Harper et al 2006). Clinical Interventions in Aging 2008:3(4) 639
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However, causality between teriparatide and osteosarcoma in 
this patient has not been established, as this was a single case 
among more than 300,000 patients worldwide treated with 
teriparatide, which is similar to the background incidence of 
osteosarcoma in the general population of men and women 
over 60 years of age . The fact that this case of osteosarcoma 
was detected early in the course of teriparatide also led to 
speculation it was pre-existing. Nevertheless, close moni-
toring for incident cases of osteosarcoma in patients treated 
with teriparatide should be continued. In addition, teripa-
ratide treatment should be avoided in patients at increased 
baseline risk for osteosarcoma, such as those with Paget’s 
disease, unexplained elevations in alkaline phosphatase, or 
prior radiation therapy involving the skeleton. Its use should 
also be limited to two years because safety and efﬁ  cacy for 
longer periods have not been evaluated (Stroup et al 2008).
Efﬁ  cacy studies of teriparatide in men
Effects of teriparatide on biochemical 
bone markers
Markers of bone formation include bone speciﬁ  c alkaline 
phosphatase (ALP), osteocalcin (OC), and C-terminal and 
N-terminal propeptides of type one procollagen (PICP 
and PINP), whereas urinary free pyridinoline (PYD), free 
deoxpyridinoline (fDPD), and N-telopeptide (NTX), as well 
as serum C-telopeptide, are markers of bone resorption. The 
measurement of bone markers in clinical trials have helped 
better understand the mechanism of action of teriparatide 
and to determine the role of these markers in the prediction 
and assessment of the response to treatment in both men and 
women with osteoporosis. Three studies conducted in men 
with osteoporosis have evaluated the effects of teriparatide 
on bone markers (Kurland et al 2000; Orwoll et al 2003; 
Finkelstein et al 2006). Markers of bone formation (bone 
ALP and PICP) and resorption (NTX and fDPD) were 
measured at baseline, 1, 3, 6, and 12 months following 
treatment with teriparatide 20 or 40 μg daily in 437 men 
with primary osteoporosis or osteoporosis due to primary 
hypogonadism (Orwoll et al 2003). Teriparatide caused 
signiﬁ  cant dose-dependent increases in both markers of bone 
formation and resorption. One month after teriparatide 20 μg 
daily, PICP levels reached their maximum (∼30% increase 
from baseline) while the ratios of urine NTX and fDPD 
corrected for creatinine were only marginally increased. 
Similar greater increments of markers of bone formation 
over bone resorption were reported in the ﬁ  rst 1–3 months 
of treatment when PICP, OC, and P1NP were measured 
(Kurland et al 2000; Finkelstein et al 2006). Changes in 
bone resorption markers after teriparatide treatment were 
similar between studies with peak levels at 6–12 months. 
Of interest is the distinct pattern of response between bone 
formation markers in the study by Orwoll et al. As opposed 
to PICP, the increment of bone ALP was gradual, reaching 
a peak at 6 months (Figure 2). These ﬁ  ndings suggest that 
different bone formation markers provide information on 
different aspects of osteoblast function and might not be 
interchangeable (Orwoll et al 2003).
Two studies have provided insight on the possible role of 
bone markers to predict the response to teriparatide (Kurland 
et al 2000; Dobnig et al 2005). The ﬁ  rst study, conducted in 
men with idiopathic osteoporosis, found that the change in 
OC at 3 months together with baseline PYD contributed 70% 
to the variance in lumbar spine BMD after 18 months of terip-
aratide treatment (Kurland et al 2000). In postmenopausal 
women, early increases in bone formation markers, and 
especially bone ALP, correlated with improvements in bone 
structure after 22 months of rPTH (1–34) (Dobnig et al 2005). 
However, no studies in men have assessed the role of bone 
markers to predict bone structure.
In summary, greater and earlier increases in bone 
formation markers compared with bone resorption markers 
after teriparatide therapy suggest that bone gain initially 
results from modeling-based bone formation without prior 
bone resorption. Later, stimulation of bone remodeling 
and in particular, bone formation, by teriparatide, provides 
additional bone gain. This is in contrast with reductions 
in bone markers typical of anti-resorptive therapy. As for 
bisphosphonates, it appears that bone markers could be 
useful as predictors of response to teriparatide treatment, 
particularly PINP and PICP.
Effects of teriparatide on BMD 
and fracture risk (Table 1)
Two main studies have evaluated the effect of teriparatide 
on BMD in men (Kurland et al 2000; Orwoll et al 2003). 
In the ﬁ  rst study, 23 men aged between 30 and 69 years 
with idiopathic osteoporosis and with or without a previous 
fracture (prevalence of fracture of 70% and 90% in the pla-
cebo and treatment groups, respectively) were randomized 
to either placebo or 400 IU (25 μg) of hPTH (1–34) for 
18 months (Kurland et al 2000). BMD was measured at 
baseline and every 6 months at the lumbar spine, hip and 
radius. A linear increase in lumbar spine BMD was observed 
in the treatment group and was already signiﬁ  cant at 6 months 
(4.8 ± 2.0% at 6 months and 13.5 ± 3.0% at 18 months), 
whereas no signiﬁ  cant change was remarkable in the placebo Clinical Interventions in Aging 2008:3(4) 640
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group. In contrast, the increase in BMD at the femoral neck 
in men treated with teriparatide was slower, only reaching 
signiﬁ  cance at 18 months (2.9 ± 1.5%; p  0.05). Finally, 
the treatment group experienced a small and non-signiﬁ  cant 
1.2 ± 0.6% decline in BMD at the 1/3 site of the radius 
compared with baseline. These results were reproduced in 
a study involving 437 men aged 30–85 years with primary 
osteoporosis or primary hypogonadism treated for a median 
of 11 months with either rPTH (1–34) 20 or 40 μg daily or 
placebo. Although the increase in lumbar spine BMD was 
less in this study, it was already signiﬁ  cant at 3 months 
(Orwoll et al 2003) (Figure 3). The response to teriparatide 
treatment was independent of gonadal status, alcohol intake 
or age.
None of these studies was specifically designed to 
address the effect of teriparatide on fracture risk in men. To 
our knowledge, the only study that evaluated this endpoint 
is a follow-up of the previously mentioned study conducted 
by Orwoll et al (Kaufman et al 2005). Eighty-one percent 
of the initial cohort of 437 hypogonadal or eugonadal men 
with osteoporosis were enrolled in the 30-month follow-
up study. Of these, 41% had known vertebral fractures at 
baseline. Baseline radiographs of the thoraco-lumbar spine 
before initiation of teriparatide were compared with those 
18 months after discontinuation of therapy in 279 subjects. 
There was a trend for the risk of new vertebral fractures to 
be reduced by 51% (p = 0.07) in men who received teripa-
ratide, corresponding to an absolute risk reduction (RR) 
of 6%. Of particular interest is the 83% reduction in the 
incidence of moderate or severe vertebral fractures in the 
combined teriparatide groups (absolute RR 5.7%; p = 0.01). 
Of the 114 men with vertebral fractures at baseline, the 
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Figure 2 Effects of teriparatide on bone formation and resorption markers. Bone ALP peaked at 6 months, whereas PICP peaked at 1 month. Both bone resorption markers 
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absolute RR for a new vertebral fracture was 13% in those 
assigned to the treatment group and no participant in this 
group experienced a moderate or severe fracture (p = 0.002 
vs placebo). This study was not powered to evaluate the 
effect of treatment on the incidence of non-vertebral or 
hip fractures.
Combination therapy with teriparatide 
and alendronate
Since teriparatide increases both bone formation and resorp-
tion, the combination with an anti-resorptive agent could 
theoretically have synergistic effects on BMD. However, 
studies in both men and women have clearly shown that 
bisphosphonates impair the ability of teriparatide or PTH 
(1–84) to increase BMD (Neer et al 2002; Black et al 
2003; Finkelstein et al 2003). The relative efﬁ  cacies of 
alendronate, teriparatide or a combination of the two were 
assessed in a study of 83 men with low BMD (Finkelstein 
et al 2003). Participants were randomly assigned to receive 
alendronate 10 mg/day, PTH 40 μg/day, or both treatments 
for 30 months. The PTH-alone group had BMD increases of 
18.1% at the posteroanterior spine and 9.7% at the femoral 
neck. These increases were signiﬁ  cantly greater than those 
observed in both the alendronate arm (7.9% and 3.2%, 
respectively) and in the combination therapy arm (14.8% 
and 6.2%, respectively). These ﬁ  ndings raise the possibility 
that bone resorption is required for teriparatide to increase 
bone formation. Measurement of bone markers in this study 
revealed that alendronate impaired the ability of teriparatide 
to increase both bone formation and bone resorption markers, 
therefore supporting this hypothesis (Finkelstein et al 2006). 
Indeed, prior bone resorption may release preformed 
growth factors necessary to trigger the anabolic effect of 
teriparatide (Oreffo et al 1989). However, a direct effect of 
Table 1 Studies evaluating the efﬁ  cacy of teriparatide in men with osteoporosis
First 
author 
year
n Baseline 
characteristics
Treatment
duration
Treatment Percent 
change in BMD 
at the lumbar 
spinea
Percent change 
in BMD at the 
femoral necka
Percent change 
in BMD at the 
1/3 site of the 
radiusa
Vertebral 
fracture 
reduction
Kurland 
2000
23 •   Idiopathic 
osteoporosis
•   Low bone 
turnover
•   Fracture history 
or back pain
• LS T-score –3.4
• FN T-score –2.0
18 mo Teriparatide 
400 IU/d 
(25 μg)
13.5 ± 3.0c 2.9 ± 1.5c –1.2 ± 0.6c •   Insufﬁ  cient 
power
Placebo NS NS NS
Orwoll 
2003
437 •     Hypogonadal 
(49%) or 
eugonadal
• LS T-score –2.2
• FN T-score –2.7
11 mo (median) Teriparatide 
20 μg/d
5.9 (5.2, 6.6)c,d 1.5 (0.9, 2.2)c,d –0.5 (–0.8, –0.1) •   51% RRR 
fracturesh
•   83% RRR 
moderate/
severe 
fracturesh
Teriparatide 
40 μg/d
9.0 (7.9, 10.1)c,d 2.9 (1.9, 4.0)c,d –0.6 (–0.9, –0.2)
Placebo NS NS NS
Finkelstein 
2003
83 •   Primary 
osteoporosis
30 mo (median) Teriparatide 
40 μg/db
18.1 (14.9, 21.3)e,f 9.7 (6.1, 13.4)e,f –0.8 (–2.3, 0.6)e,f –
•   LS or FN 
T-score  –2.0
Alendronate 
10 mg/d
7.9 (6.3, 9.4)e,g 3.2 (1.5, 4.8)e 1.0 (0.2, 1.8)e
Bothb 14.8 (12.4, 17.3)f,g 6.2 (4.0, 8.4)f 1.0 (–0.1, 2.1)f
aMean percentage change in BMD ± SEM or mean percentage change in BMD (95% CI) at the study endpoint.
bTeriparatide was begun at month 6.
cp  0.05, teriparatide 20 μg/d or 40 μg/d vs placebo.
dp  0.05, teriparatide 20 μg/d vs 40 μg/d.
ep  0.05, teriparatide 40 μg/d vs alendronate.
fp  0.05, teriparatide 40 μg/d vs combination alendronate 10 mg/d and teriparatide 40 μg/d.
gp  0.05, alendronate 10 mg/d vs combination alendronate 10 mg/d and teriparatide 40 μg/d.
hComparison of radiographs at baseline and 18 months after discontinuation of teriparatide or placebo in 279 of the 355 subjects who enrolled in the follow-up study (Kaufman 
et al 2005). At that time, 36% and 25% of the men who were previously in the placebo and combined teriparatide arms, respectively, were receiving an anti-osteoporosis drug. 
Bisphosphonates accounted for 75% of osteoporosis therapy and testosterone was the second most common.
Abbreviations: LS, lumbar spine; FN, femoral neck; BMD, bone mineral density; Mo, months; NS, not signiﬁ  cant; RRR, relative risk reduction.Clinical Interventions in Aging 2008:3(4) 642
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alendronate on osteoblasts cannot be excluded and it is still 
possible that teriparatide stimulates directly bone forma-
tion independently of its effect on bone resorption through 
mechanisms previously explained. In conclusion, these data 
indicate teriparatide should be initiated as monotherapy, 
because combination with anti-resorptive agents attenuates 
its anabolic effect.
Effect of previous bisphosphonate 
therapy on efﬁ  cacy of teriparatide
Given that teriparatide is costly and generally approved as 
second-line therapy in most countries, the great majority of 
men with osteoporosis encountered in clinical practice will 
have already received a course of bisphosphonates prior to 
initiation of teriparatide. The ensuing important question is 
whether previous treatment with bisphosphonates reduces 
the efﬁ  cacy of teriparatide. Finkelstein et al (2006) compared 
the increase in bone formation and bone resorption markers 
following teriparatide started at baseline for 30 months or 
preceded by 6 months of alendronate 10 mg daily in 63 men 
with low bone mass. Alendronate clearly reduced the ability 
of teriparatide to increase both bone formation and resorp-
tion markers. In the only study including men (29 men 
and 35 women) with osteoporosis, Handler retrospectively 
compared the effect of 18–24 months of teriparatide on 
BMD in patients previously treated with iv bisphosphonates 
(group 1, n = 36) or oral bisphosphonates (group 2, n = 16) 
vs treatment naïve patients (group 3, n = 12) (Handler 
2008). Annualized average BMD gain, assessed by spine 
computerized vertebral tomography (QCT), was 7%, 4%, 
and 16% in groups 1, 2, and 3, respectively. Patients who 
received iv or oral bisphosphonates were also more likely 
than treatment naïve patients to be non-responders (14% 
and 25% vs 0%, respectively) deﬁ  ned as further bone loss 
or 1% annualized gain under treatment. Of interest, the 
time lag between the last dose of bisphosphonate and ini-
tiation of teriparatide positively inﬂ  uenced the response to 
teriparatide. Although current evidence in men is scarce, it 
is consistent with a blunting of the effect of teriparatide on 
bone markers and BMD when administered after a course 
of bisphosphonates.
Initiation of therapy after discontinuation 
of teriparatide
Because of the osteosarcoma concerns, teriparatide therapy 
is currently approved for 18 to 24 months, depending on the 
country. After this period, switching to a bisphosphonate is 
recommended to maintain and perhaps increase the gains 
obtained during teriparatide treatment. Indeed, rapid loss 
of BMD occurred after discontinuation of teriparatide in 
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Figure 3 Mean percentage changes in bone mineral density at the lumbar spine, femoral neck, total hip and distal radius following a median of 11 months of teriparatide 20 or 
40 μg/d vs placebo. Bars represent the SEM.   Adapted from Orwoll ES, Scheele WH, Paul S, et al 2003. The effect of teriparatide [human parathyroid hormone (1–34)] therapy 
on bone density in men with osteoporosis. J Bone Miner Res, 18:9–17.   With permission of the American Society for Bone and Mineral Research.
*p  0.05, teriparatide 20 μg/d vs placebo.
**p  0.001, teriparatide 20 μg/d vs placebo.
+p  0.05, teriparatide 20 μg/d vs teriparatide 40 μg/d.
++p  0.001, teriparatide 20 μg/d vs teriparatide 40 μg/d.Clinical Interventions in Aging 2008:3(4) 643
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men with idiopathic osteoporosis (Kurland et al 2004). 
Furthermore, additional gains in lumbar spine BMD were 
demonstrated if a bisphosphonate was administrated 
immediately after cessation of hPTH (1–34), with a 4-fold 
cumulative increase in lumbar spine BMD at two years in 
those who took a bisphosphonate compared to those who 
delayed bisphosphonate therapy or who received no treatment 
(23.6%, 11.1%, and 5.5%, respectively). Noteworthy, the use 
of teriparatide for a mean of 22 months did not appear to blunt 
the ability of bone to subsequently respond to a bisphospho-
nate. These ﬁ  ndings are interesting and suggest that when 
bisphosphonates are initiated after a course of teriparatide, 
they enhance mineralization of the newly formed and less 
mineralized bone produced by the action of teriparatide on 
osteoblasts (Kurland et al 2004).
Monitoring of treatment
Although dual X-ray absorptiometry (DXA) is considered 
to be the gold standard for monitoring the response to 
osteoporosis treatment, the best method of monitoring a 
patient’s response to anabolic drug treatment is still being 
debated. Within the ﬁ  rst year of therapy using teriparatide, 
BMD typically increases at the spine and to a lesser extent at 
the proximal femur. Conversely, decreases in BMD may be 
observed in areas of predominantly cortical bone, such as the 
distal radius. The latter may result from a relatively greater 
increase in bone diameter compared with cortical thickness 
(Stroup et al 2008). Of note is the ﬁ  nding that increased 
lumbar spine BMD accounts for only 30%–41% of the ver-
tebral fracture risk reduction following teriparatide therapy, 
suggesting that improvements in non-BMD determinants 
of bone strength, such as increases in bone thickness and 
diameter, also play an important role (Chen et al 2006). 
Through stimulation of bone remodeling, teriparatide 
could also improve bone quality by reducing the amount of 
microdamage, and by removing highly mineralized bone.
Despite the limitations of DXA, current recommenda-
tions regarding monitoring of teriparatide therapy suggest 
annual or 2-yearly DXA scans, similar to the evaluation 
of response to anti-catabolic agents. QCT is an attractive 
technique that could provide complementary information 
on the effects of teriparatide on bone microarchitecture and 
structure. However, the lack of availability, high radiation 
exposure and high coefﬁ  cient of variation outside clinical 
trials currently limit the use of this modality in the clinical 
setting. Measurement of serum markers of bone formation, 
particularly PINP or PICP at baseline and after 3–6 months 
of treatment, may provide another method of monitoring the 
efﬁ  cacy of teriparatide treatment and help assess medication 
adherence (Kurland et al 2000; Eastell et al 2006). It is, 
however, important to remember that bone markers are 
subject to intra-individual variability (Ebeling and Akesson 
2001) especially if not sampled correctly or when measured 
in routine clinical practice. Therefore, results should be 
interpreted with caution and take into account these possible 
limitations.
Patient perspective: compliance
and reduction of back pain
Compliance with daily injections of teriparatide as well 
as patient satisfaction and acceptability of this treatment 
were assessed in a study of 116 men and women with 
osteoporosis (Adachi et al 2007). Reported compliance was 
excellent with 89% and 82% of the participants still taking 
the medication at 6 months and 18 months, respectively. 
Globally, patient satisfaction with teriparatide was 73% at 
3 months, 77% at 6 months, and 86% at 18 months. The 
compliance with teriparatide in this study is similar to 
the one reported in clinical trials of teriparatide and is in 
contrast with the 50%–75% discontinuation rate observed 
after 1 year of oral bisphosphonate therapy (McCombs et al 
2004; Cramer et al 2005). This study also demonstrates 
that the initial fear of injections is usually overcome after 
a few months of treatment and does not impede patient 
satisfaction.
Another advantage of teriparatide over bisphosphonates 
is the reduction of back pain. A meta-analysis comprising 
4 randomized and controlled trials, of which 1 was performed 
in men with idiopathic or hypogonadal osteoporosis (Orwoll 
et al 2003), showed that severe back pain was reduced by 
61% in the pooled teriparatide vs the pooled comparators 
trials (placebo, alendronate, or hormonotherapy) (Nevitt et al 
2006). The risk reduction for any back pain was evident after 
only 6 months of teriparatide. In particular, the results were 
not different across trials, supporting a similar effect in both 
men and women. This study also suggests that the beneﬁ  cial 
effect of teriparatide on back pain may be explained by a 
reduction in vertebral fractures.
Conclusion
Reduced bone formation with resulting thinning of trabecu-
lar bone in excess of cortical bone in men with osteopo-
rosis makes teriparatide an especially attractive treatment 
for men. However, until further studies demonstrate its 
efﬁ  cacy on reducing non-vertebral and hip fractures and 
the cost of teriparatide is reduced, teriparatide should be Clinical Interventions in Aging 2008:3(4) 644
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restricted to patients at high risk of an osteoporotic fracture, 
who are unable to tolerate anti-catabolic therapy, or who 
have worsening BMD or persistently low BMD, or suffer 
fractures while receiving anti-catabolic therapy (Stroup 
et al 2008).
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